Certain momentum stocks might have had their day in the sun, Paul Hickey of Bespoke Investment Group said Tuesday.
"Overall, the market is slightly overvalued, but in certain areas of the market, you're very overvalued in stocks," he said on CNBC's "Halftime Report."
Hickey noted that biotech, which saw a selloff recently, and small-cap stocks were "at historically high valuations" relative to large-cap names.
"These momentum names go up on hopes and dreams … and then when they go down, you're suddenly saying, 'Wait, why did I own this in the first place?'" he said.
Hickey also cited "low-quality IPOs coming to market" as a sign that there was weakness in the stock market, noting that there hasn't been an initial public offering of more than $250 million in two months.
"You don't want to be investing in a lot of them ," he said. "They don't have earnings. They don't expect to have earnings."
(Watch video: Daring to short biotech)
But once IPOs start to get shelved, Hickey added, the selloff has run its course.
"I would stay away from these things unless you're getting a chance to flip them," he said.
Momentum stocks, those in which prices have outpaced valuations, were also worth avoiding, too, Scaramucci added—with the possible exception of such companies as Google and Facebook. They "can support the valuations, I think," he said.
Trader disclosure: On March 25, 2014, the following stocks and commodities mentioned or intended to be mentioned on CNBC's "Fast Money" were owned by the "Fast Money" traders: Anthony Scaramucci is long AAPL, CSCO, GOOG, HPQ, DIS; Pete Najarian is long stock AAPL, long calls BAC, C, GS, JPM, YHOO, SBUX, MSFT, EBAY, HPQ, GM, MU, TIF, ASH; Mike Murphy is long AAPL, FB, BAC, C, MU, WFM, COG; Stephanie Link is long GOOG, FB, GS, JPM, BAC, CMI, ETN, CELG, COST.